Orexigen Therapeutics' (NASDAQ:OREX) re-launch of Contrave continues to be successful, with an 18% increase in prescriptions in the United States in Q217 compared to Q117. Importantly, net revenue per unit sold increased 37%, indicating better coverage and less discounting. Outside of the US, progress continues as the product has launched in 17 countries, with another 10-15 expected by Q118, including Germany and Italy. The company has also announced that it has commenced an exploration of strategic transactions as a means to maximize the value creation for shareholders.
Continued success in patient-centric campaign
A shift from previous partner Takeda’s healthcare provider-focused marketing to a campaign focused on consumers (but with continued detailing of high prescribing physicians) has yielded a dramatic increase in prescriptions. Prescriptions increased 39% in Q117 compared to the prior quarter and a further 18% in Q217. They now have approximately 50% of the branded obesity market (~8.5% of the total) according to Symphony Health.
To read the entire report Please click on the pdf File Below: